Single-dose nirsevimab successfully reduced rates of respiratory syncytial virus-associated lower respiratory infections and hospitalizations in pre-term infants.
An investigational inactivated whole-virus COVID-19 vaccine has demonstrated safety and immunogenicity, according to an interim analysis.
Influenza vaccinations were found to be underutilized among groups who are considered to be at high risk for complications from infection.
Influenza vaccination should occur by the end of October, if possible.
HHS issued the amendment in order to increase access to childhood vaccines and decrease the risk of vaccine-preventable disease outbreaks as children return to daycare and school.
Most pediatric practitioners do not counsel families to wait 3 days or longer between introducing new foods for infants.
The FDA is expected to make a decision by the first quarter of 2021.
Vaccines are a key public health strategy that is remarkably safe due to continued postmarketing surveillance programs.
Review of the Advisory Committee Immunization Practices updates to the pediatric immunization schedule and significant revisions to the adult immunization schedule.
Family physicians and pharmacists identified areas for improvement in antibiotic allergy documentation to prevent the prescribing of suboptimal treatments.
Simulation experiments demonstrated that a vaccine efficacy of 80% is required to extinguish the ongoing COVID-19 pandemic without any other additional measures.
The trial, which is the first to be implemented under Operation Warp Speed, is expected to enroll around 30,000 adults and will be conducted at multiple clinical research sites across the US.
The analysis included 241,551 patients monitored for a median of 4 years.
The researchers found 28.9% of pediatricians with knowledge of the guidelines reported full implementation, while 64.3% reported partial implementation.
The FDA has granted Fast Track designation to 2 of Pfizer and BioNTech’s vaccine candidates against COVID-19.
A mathematical model shows that SARS-CoV-2 disease-induced herd immunity level may be lower than the classical model assuming homogenous immunization.
A team of investigators report on the findings from a randomized controlled trial of 3 enhanced influenza vaccines and a standard-dose vaccine in older adults.
A large clinical trial of the first US COVID-19 vaccine could begin next month, according to Moderna Inc., which developed the vaccine with the US National Institutes of Health.
Researchers sought to analyze the immune status of newborns from mothers with COVID-19 in the third trimester.
The purpose of this project is to implement and evaluate the effectiveness of the 4 Pillars Practice Transformation Program to increase uptake of the HPV vaccine among pediatric patients.